Biomarkers can make brain and mental health care feel more concrete: a blood result, a scan finding, a spinal fluid measure, a genetic result, or a signal from a wearable device. But the word is often used too broadly. Not every test, score, symptom pattern, app metric, or brain image is a biomarker, and even a real biomarker does not automatically diagnose a condition by itself.
The distinction matters because biomarkers can guide testing, clarify risk, support a diagnosis, monitor disease activity, or help decide whether a treatment is appropriate. They can also be misunderstood, overmarketed, or used outside the setting where they were validated. In brain and mental health, where symptoms, biology, life context, and function often overlap, biomarkers are most useful when they are interpreted as part of a careful clinical assessment rather than as a shortcut around one.
Table of Contents
- What Counts as a Biomarker
- Types of Biomarkers and Their Uses
- Biomarkers in Brain Health Testing
- Why Mental Health Biomarkers Are Difficult
- Digital Biomarkers and Passive Monitoring
- How Biomarkers Fit Into Diagnosis
- Limits, Risks, and Common Misunderstandings
- When Symptoms Need Urgent Evaluation
What Counts as a Biomarker
A biomarker is a measurable biological characteristic that gives information about normal biology, disease biology, risk, exposure, or response to treatment. It is not simply any useful health clue. A symptom, a questionnaire score, or a person’s daily functioning may be clinically important, but it is not usually a biomarker unless it directly measures a biological feature.
In brain and mental health, biomarkers can come from several sources:
- Blood, such as phosphorylated tau in Alzheimer’s disease evaluation or thyroid hormone levels when mood and cognition change.
- Cerebrospinal fluid, such as amyloid and tau measures used in some cognitive disorder workups.
- Brain imaging, such as amyloid PET, tau PET, MRI evidence of stroke, or patterns of brain atrophy.
- Electrical and physiological testing, such as EEG findings in seizure evaluation.
- Genetics, such as variants that increase risk for certain neurological conditions.
- Digital physiology, such as heart rate variability or sleep-wake rhythm data when collected and interpreted in a clinically meaningful way.
The key word is “biological.” A depression questionnaire score can help screen for depression, but the score itself is not a biomarker. A cognitive test score can show memory or attention problems, but the score is a performance measure, not a biological marker. A brain scan can be a biomarker when it measures a disease-related biological feature, but a scan that is normal or nonspecific may not answer the mental health question being asked. For example, a person wondering whether imaging can prove depression, anxiety, ADHD, or autism may need a clearer explanation of what brain scans can and cannot show.
A practical way to judge whether something counts is to ask: what biological feature is being measured, and what has it been validated to indicate? If the answer is “a symptom pattern,” “a behavior,” or “a risk estimate based mostly on self-report,” it may still be useful, but it should not be treated as a biomarker in the strict medical sense.
Types of Biomarkers and Their Uses
Biomarkers are useful only when their purpose is clear. The same biological measure can mean different things depending on whether it is being used to estimate risk, support diagnosis, track change, predict treatment response, or monitor safety.
Clinical and research settings often describe biomarkers by their “context of use.” That phrase means the specific job the biomarker is expected to do, in a specific group of people, under specific conditions. A biomarker validated for one job should not automatically be used for another.
| Biomarker type | What it helps answer | Brain or mental health example |
|---|---|---|
| Risk or susceptibility | Is this person more likely to develop a condition? | APOE genotype as one part of Alzheimer’s risk assessment |
| Diagnostic | Does this biological pattern support a diagnosis? | Amyloid PET or CSF amyloid/tau patterns in Alzheimer’s disease evaluation |
| Monitoring | Is the biological state changing over time? | Repeated imaging or lab markers in selected neurological diseases |
| Predictive | Is a treatment more or less likely to work? | Some pharmacogenomic tests may inform medication metabolism, though they rarely choose a psychiatric medication by themselves |
| Safety | Is a treatment causing risk or harm? | Blood levels and kidney or thyroid monitoring during lithium treatment |
| Response | Is the body responding biologically to treatment? | Changes in a disease-related protein measure during a clinical trial |
This is why a “positive” result is not always the same as a diagnosis. A risk biomarker may increase the probability of a condition but not prove that the person has it. A diagnostic biomarker may support one explanation for symptoms but still need to be weighed against medical history, exam findings, medications, sleep, mood, substance use, and other possible causes. A safety biomarker may be essential for monitoring treatment, even though it says little about the original diagnosis.
Genetic results are a common source of confusion. Some genetic tests identify rare inherited neurological conditions or guide family counseling. Others estimate risk without predicting whether a person will definitely develop symptoms. In psychiatric care, genetics may contribute to research and medication planning, but most mental health conditions are influenced by many genes plus environment, stress, development, sleep, substances, medical conditions, and life history. That is why genetic testing for brain and mental health conditions has to be interpreted with care.
Biomarkers in Brain Health Testing
Biomarkers are most established in parts of neurology, especially cognitive disorders, seizure evaluation, inflammatory diseases, infections, tumors, stroke, and some genetic or metabolic conditions. They are less definitive for most everyday complaints such as brain fog, stress-related concentration problems, or nonspecific fatigue.
Alzheimer’s disease is one of the clearest examples of how biomarkers are changing clinical practice. Historically, Alzheimer’s was diagnosed mainly by the pattern of symptoms and by ruling out other causes of memory loss. Today, amyloid and tau biomarkers can help show whether Alzheimer’s-type biology is present. These biomarkers may be measured through PET imaging, cerebrospinal fluid, and, increasingly, blood tests in specialized settings. In 2025, the FDA cleared a blood test to aid in detecting amyloid pathology associated with Alzheimer’s disease in symptomatic adults being evaluated in specialized care. That does not make blood testing a stand-alone screening tool for everyone, but it does show how biomarker testing is becoming more accessible.
Different biomarker methods answer different questions:
| Test type | What it may show | Important limitation |
|---|---|---|
| Blood biomarker tests | Proteins linked with Alzheimer’s pathology, inflammation, metabolic disease, vitamin deficiency, thyroid disease, or other contributors | Availability, accuracy, and interpretation vary by test and clinical setting |
| CSF testing | Amyloid, tau, infection, inflammation, autoimmune markers, or other nervous system clues | Requires lumbar puncture and is used selectively |
| PET imaging | Amyloid, tau, glucose metabolism, or other molecular patterns depending on tracer | Cost, access, radiation exposure, and context-specific interpretation matter |
| MRI | Stroke, tumor, inflammation, atrophy, vascular disease, structural changes, or injury | Often does not explain psychiatric symptoms by itself |
| EEG | Electrical brain activity patterns, especially in seizure or encephalopathy evaluation | Not a general-purpose test for most mental health diagnoses |
A person with memory loss may have cognitive testing, blood work, brain imaging, and, in selected cases, Alzheimer’s biomarkers. A person with sudden confusion may need urgent evaluation for delirium, infection, medication effects, stroke, seizure, or metabolic problems. A person with chronic brain fog may need a different workup that looks at sleep, mood, blood sugar, thyroid function, anemia, B12, medications, and other common contributors before advanced biomarker testing is considered.
For people specifically comparing Alzheimer’s biomarker options, it can help to understand how blood biomarker tests for Alzheimer’s disease, amyloid PET scans, and CSF testing in cognitive disorders differ in invasiveness, access, and interpretation.
Why Mental Health Biomarkers Are Difficult
Most mental health diagnoses still depend on clinical assessment, not a single biological test. This is not because mental health conditions are “less real.” It is because the biology of mood, anxiety, psychosis, trauma, attention, sleep, and behavior is complex, overlapping, and influenced by many systems at once.
A major challenge is heterogeneity. Two people with major depression can have different symptom profiles, sleep patterns, appetite changes, stress histories, medical conditions, inflammatory states, medication exposures, and family histories. One person may have slowed thinking and early-morning waking; another may sleep excessively, feel physically heavy, and experience intense rejection sensitivity. A single blood marker or scan pattern is unlikely to capture all of that.
Another challenge is overlap across diagnoses. Sleep deprivation can mimic ADHD. Trauma can look like anxiety, irritability, dissociation, depression, or concentration problems. Bipolar depression can resemble unipolar depression until a careful history identifies past hypomania or mania. Substance use, thyroid disease, anemia, vitamin B12 deficiency, autoimmune disease, medication side effects, and neurological conditions can all affect mood or cognition. In these situations, the diagnostic question is not “Which biomarker gives the label?” but “What combination of history, exam, screening, labs, and follow-up best explains the person’s symptoms?”
This is why screening tools and diagnostic evaluations remain central. A questionnaire can identify symptom severity and guide next steps, but it is different from a biological test. A high PHQ-9 score, GAD-7 score, ADHD rating scale result, or PTSD screen can be clinically meaningful, yet it does not function like a lab test for a disease protein. When results are unclear, the distinction between screening and diagnosis in mental health becomes especially important.
Some biomarkers do matter in mental health care, but often indirectly. Thyroid testing may reveal a medical contributor to anxiety, depression, or brain fog. Toxicology screening may clarify substance-related symptoms. Sleep studies can identify sleep apnea that worsens mood and concentration. Medication blood levels can improve safety. Pharmacogenomic testing may help explain how someone metabolizes certain medications, although it does not replace clinical judgment about which treatment is best.
The most accurate framing is that mental health biomarkers are promising but limited. They may help define subtypes, detect medical mimics, improve treatment monitoring, or support research. For most psychiatric diagnoses, however, they do not yet replace a skilled clinical evaluation.
Digital Biomarkers and Passive Monitoring
Digital biomarkers are measurements collected through digital tools that may reflect biological or physiological processes. Wearables, smartphones, sleep trackers, typing patterns, voice features, activity sensors, and heart rate data can all generate health-related signals, but not every digital signal is a biomarker.
This area is growing quickly because digital tools can measure patterns outside the clinic. A person’s sleep timing, daily activity, heart rate variability, movement, speech rhythm, or social rhythm may change before a relapse of depression, mania, psychosis, or cognitive decline. These patterns can be useful, especially when they are tracked over time and interpreted alongside symptoms.
The problem is terminology. A wearable heart rate measure is closer to a biological or physiological marker than a phone’s screen time. GPS location patterns, typing speed, app use, and call frequency may reflect behavior, routine, isolation, or functioning, but they are not automatically biological markers. They may be better described as digital phenotypes, behavioral signals, or passive monitoring data unless there is a validated biological pathway and a clinically tested interpretation.
Digital monitoring can offer practical benefits:
- It may show changes that a person does not notice in the moment.
- It can capture sleep and activity patterns between appointments.
- It may help clinicians and patients discuss relapse warning signs.
- It can support measurement-based care when privacy, consent, and validation are handled properly.
It also raises real concerns. Data may be incomplete, inaccurate, or influenced by device use habits. Algorithms may work differently across age groups, cultures, disabilities, languages, and socioeconomic settings. A low activity day may reflect depression, pain, caregiving demands, weather, shift work, illness, or simply a dead battery. Privacy risks are especially important when mental health data includes location, communication patterns, sleep, or social behavior.
People using wearables or apps for mental health should ask what is being measured, whether the measure has been validated for their situation, who can see the data, how alerts are handled, and whether the tool supports care rather than replacing it. For a deeper look at this area, digital biomarkers for brain health explains how wearables, apps, and passive monitoring are being used and where the limits remain.
How Biomarkers Fit Into Diagnosis
A biomarker result is strongest when it answers a specific clinical question. It is weakest when it is ordered broadly, interpreted in isolation, or used to explain symptoms that could have many different causes.
A careful diagnostic process usually starts with the person, not the test. Clinicians consider the timeline of symptoms, age of onset, medical history, medications, substance use, sleep, stressors, family history, neurological signs, functional changes, and safety concerns. Testing is then chosen to narrow the possibilities.
For example, memory loss in an older adult might raise questions about normal aging, mild cognitive impairment, Alzheimer’s disease, vascular cognitive impairment, depression, sleep apnea, medication effects, thyroid disease, B12 deficiency, or delirium. Biomarkers may help if the clinical picture points toward a neurodegenerative process, but they are not the first or only step. Cognitive testing still describes the pattern of strengths and weaknesses. Blood work may identify reversible contributors. MRI may show vascular disease or other structural findings. Alzheimer’s biomarkers may help determine whether amyloid or tau pathology is present.
Mental health evaluations work similarly. If someone has panic symptoms, the clinician may consider panic disorder, thyroid disease, arrhythmia, stimulant exposure, medication effects, trauma, or substance withdrawal. If someone has low mood and poor concentration, the differential may include depression, ADHD, grief, sleep deprivation, anemia, perimenopause, chronic stress, or bipolar disorder. Biomarkers and lab tests can help rule in or rule out medical contributors, but diagnosis usually depends on the full pattern.
A useful biomarker discussion should include these questions:
- What condition or biological process is this test meant to assess?
- Was the test validated for someone with my symptoms and age group?
- Is it being used for screening, diagnosis, risk assessment, treatment selection, or monitoring?
- What would a positive, negative, or indeterminate result change?
- What are the possible false positive and false negative consequences?
- Does the result need confirmation with another test or specialist evaluation?
- How does the result fit with my symptoms, exam, and functional changes?
These questions are especially important after confusing or unexpected results. An abnormal scan or test can feel alarming, but many findings need context. Some are incidental, age-related, nonspecific, or unrelated to the main symptoms. Others do require prompt follow-up. When a result is abnormal, what happens after abnormal brain scan or cognitive test results depends on the type of finding, the symptoms, and the level of urgency.
Limits, Risks, and Common Misunderstandings
The biggest misunderstanding is that biomarkers are always more objective, more accurate, or more meaningful than clinical judgment. A biomarker may be objective in the sense that it produces a number or image, but interpretation still depends on context, test quality, pretest probability, and the person’s actual symptoms.
False positives and false negatives matter. A false positive biomarker result can lead to anxiety, stigma, unnecessary treatment, insurance concerns, extra testing, or a delayed search for the real cause. A false negative can offer false reassurance or delay care. Indeterminate results can also occur, especially when biology falls near a cutoff or when sample handling, assay performance, or patient factors complicate interpretation.
Another risk is overclaiming. Some commercial tests imply that they can identify the biological cause of depression, anxiety, ADHD, autism, brain fog, or cognitive decline from a scan, blood panel, qEEG, genetic profile, or app-based pattern. Some tests may provide useful information in narrow contexts, but broad claims should be viewed carefully. A test should be judged by what it has been validated to do, not by how scientific it sounds.
There are also equity and access concerns. Advanced biomarker testing may be expensive, unavailable in some regions, or easier to access for people who already have specialty care. If a biomarker becomes part of treatment eligibility, access to testing can affect access to treatment. At the same time, poorly validated testing can expose people to cost and confusion without improving care.
Biomarkers can also reshape identity. A person told they have a risk marker for dementia, a genetic vulnerability, or a digital pattern associated with relapse may feel labeled before symptoms are clear. This is one reason pretest counseling, informed consent, and careful result communication are important. For some results, especially genetic and dementia-related findings, it may be helpful to discuss possible emotional, family, insurance, and planning implications before testing.
A balanced view is best: biomarkers can be powerful tools, but they are tools. They should make care clearer, safer, or more precise. If a result does not change diagnosis, monitoring, treatment, prevention, or decision-making, it may not be worth the cost or stress.
When Symptoms Need Urgent Evaluation
Biomarker testing should never delay urgent care when symptoms suggest a medical or psychiatric emergency. Some brain and mental health symptoms need immediate evaluation because timing can affect safety, treatment options, and outcomes.
Seek urgent medical or emergency help for symptoms such as:
- Sudden weakness, facial drooping, trouble speaking, severe dizziness, or vision loss.
- New seizure, loss of consciousness, or repeated episodes of confusion.
- Sudden severe headache, especially if it is the worst headache of the person’s life.
- Rapidly worsening confusion, agitation, hallucinations, or disorientation.
- New suicidal thoughts, intent, plan, or inability to stay safe.
- Thoughts of harming someone else.
- New psychosis, mania, or dangerous behavior.
- Severe medication reaction, suspected overdose, intoxication, withdrawal, or lithium toxicity.
- Fever, stiff neck, severe headache, and confusion.
- Head injury followed by worsening headache, vomiting, confusion, weakness, or unusual behavior.
In these situations, the first priority is stabilization and time-sensitive evaluation, not outpatient biomarker interpretation. Emergency clinicians may use blood tests, toxicology screening, CT, MRI, EEG, lumbar puncture, or other tools depending on the symptoms, but those tests are chosen to address immediate risks.
For non-urgent symptoms, the best next step is usually a primary care, neurology, psychiatry, psychology, sleep medicine, or neuropsychology evaluation depending on the main concern. Biomarkers may become part of that process, but they work best when they are guided by a clear question: what needs to be explained, ruled out, confirmed, monitored, or treated?
If you are unsure whether symptoms are urgent, it is safer to seek timely medical advice rather than waiting for a specialty test. For a symptom-focused safety framework, when to go to the ER for mental health or neurological symptoms can help clarify which changes need immediate attention.
References
- BEST (Biomarkers, EndpointS, and other Tools) Resource 2025 (Glossary)
- Revised criteria for diagnosis and staging of Alzheimer’s disease 2024 (Guideline)
- Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape 2023 (Review)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease 2025 (Regulatory Statement)
- Aligning digital biomarker definitions in psychiatry with the National Institute of Mental Health Research Domain Criteria framework 2024 (Perspective)
- Convergence of digital health technologies and biomarkers 2022 (Review)
Disclaimer
This article is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Biomarker results for brain, cognitive, or mental health concerns should be interpreted by qualified clinicians in the context of symptoms, history, exam findings, and other relevant testing.
Share this article on Facebook, X, or your preferred platform to help others understand what biomarkers can—and cannot—tell us about brain and mental health.
